Testing a new antibiotic for hard-to-treat resistant tuberculosis

Plain-English translation of NCT05824871 on ClinicalTrials.gov ↗ · Source last updated June 2025 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called to treat a serious form of tuberculosis that doesn't respond to standard antibiotics. Researchers want to know if , combined with other TB medicines, can help people recover from this hard-to-treat infection. The medication will be compared against another established TB drug to see which works better.

Drug-resistant tuberculosis is much harder to cure and requires longer, more complicated treatment. This medication is being tested because it may offer patients a more effective option when standard TB drugs no longer work.

Do you qualify?

You likely qualify if…

you have been diagnosed with tuberculosis that is resistant to rifampicin (a standard TB antibiotic)
you have tested positive for TB bacteria in your sputum (coughed-up fluid)
your body weight is between 40 and 90 kilograms, and your BMI is between 15 and 28
you are willing to stop any previous TB medicines and wait 7 days before starting this study
you are not pregnant or breastfeeding, or you agree to use reliable birth control throughout treatment

You likely don't qualify if…

you are allergic to any of the study medications or their ingredients
you have a history of drug or alcohol dependence
you have tuberculosis that has spread to other parts of your body beyond your lungs
you have a heart condition or history of dangerous heart rhythms
you are living with HIV, or you have taken the comparison drug Bedaquiline before

What participation looks like

You will be randomly assigned to receive either the new medication () or an established TB drug (), both combined with other standard TB medicines. The new medication involves taking a higher starting dose for 2 weeks, then a lower maintenance dose for 22 more weeks; the comparison drug has a different dosing schedule. After 24 weeks of this intensive phase, you will continue taking your regular TB medicines until week 72 (about 6 months total). Throughout the study, you'll have regular check-ins to monitor how well the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Testing a new antibiotic for hard-to-treat resistant tuberculosis

What is this trial?

Do you qualify?

What participation looks like

Trial locations